{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-04T23:12:14.654202+00:00","company":{"ticker":"NMRA","cik":1885522,"company_name":"Neumora Therapeutics, Inc."},"pagination":{"limit":100,"returned":13,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"e464bfb2123dbea8bed820afc247ed4f8b5f23f1","cik":1885522,"ticker":"NMRA","company_name":"Neumora Therapeutics, Inc.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$53.5 million","period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":null},"claim":"Neumora Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $53.5 million.","evidence_excerpt":"compared to $18.8 million for the same period in 2025. The decrease was primarily attributable to lower personnel-related costs. • Net Loss: The Company reported a net loss of $53.5 million for the first quarter of 2026, as compared to $68.0 million for the same period in 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-210310","anchor_url":"https://secwatch.observer/filing/0001193125-26-210310#claim-e464bfb2123dbea8bed820afc247ed4f8b5f23f1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312526210310/0001193125-26-210310-index.htm"},{"fact_type":"earnings_release","fact_key":"9463cc4819a12041dbc470d8d38bb9791d495094","cik":1885522,"ticker":"NMRA","company_name":"Neumora Therapeutics, Inc.","filed_at":"2026-03-30T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and full year ended December 31, 2025","report_date":"2026-03-30","result_type":"reported_results","revenue_text":null},"claim":"Neumora Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.","evidence_excerpt":"On March 30, 2026, Neumora Therapeutics, Inc. (“Neumora” or the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-130372","anchor_url":"https://secwatch.observer/filing/0001193125-26-130372#claim-9463cc4819a12041dbc470d8d38bb9791d495094","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312526130372/0001193125-26-130372-index.htm"},{"fact_type":"executive_change","fact_key":"9643877801","cik":1885522,"ticker":"NMRA","company_name":"Neumora Therapeutics, Inc.","filed_at":"2025-02-21T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-02-14","interim":false,"role":"Chairman and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Paul L. Berns was appointed as Chairman and Chief Executive Officer at Neumora Therapeutics, Inc..","evidence_excerpt":"an Executive Employment Agreement, effective as of February 14, 2025, with Paul L. Berns, as the Company’s Chairman and Chief Executive Officer","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-031974","anchor_url":"https://secwatch.observer/filing/0001193125-25-031974#claim-9643877801","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525031974/0001193125-25-031974-index.htm"},{"fact_type":"executive_change","fact_key":"36bcff4dfd","cik":1885522,"ticker":"NMRA","company_name":"Neumora Therapeutics, Inc.","filed_at":"2025-02-21T23:59:59+00:00","payload":{"action":"separated","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-14","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":"Paul L. Berns","successor_named":true},"claim":"Henry Gosebruch departed as President and Chief Executive Officer at Neumora Therapeutics, Inc..","evidence_excerpt":"the Company has entered into a Separation Agreement, dated February 14, 2025, with Henry Gosebruch, the Company’s former President and Chief Executive Officer","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-031974","anchor_url":"https://secwatch.observer/filing/0001193125-25-031974#claim-36bcff4dfd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525031974/0001193125-25-031974-index.htm"},{"fact_type":"executive_change","fact_key":"d57e56ad54","cik":1885522,"ticker":"NMRA","company_name":"Neumora Therapeutics, Inc.","filed_at":"2025-02-13T23:59:59+00:00","payload":{"action":"departed","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-14","interim":false,"role":"Chief Commercial Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Kaya Pai Panandiker departed as Chief Commercial Officer at Neumora Therapeutics, Inc..","evidence_excerpt":"Kaya Pai Panandiker will depart the Company and no longer serve as Chief Commercial Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-026156","anchor_url":"https://secwatch.observer/filing/0001193125-25-026156#claim-d57e56ad54","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm"},{"fact_type":"executive_change","fact_key":"613e0fbbd4","cik":1885522,"ticker":"NMRA","company_name":"Neumora Therapeutics, Inc.","filed_at":"2025-02-13T23:59:59+00:00","payload":{"action":"transitioned","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-02-14","interim":false,"role":"Chief Strategy Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Carol Suh changed role as Chief Strategy Officer at Neumora Therapeutics, Inc..","evidence_excerpt":"Carol Suh will transition from the role of Chief Operating Officer to Chief Strategy Officer","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-026156","anchor_url":"https://secwatch.observer/filing/0001193125-25-026156#claim-613e0fbbd4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm"},{"fact_type":"executive_change","fact_key":"bcba4e24f6","cik":1885522,"ticker":"NMRA","company_name":"Neumora Therapeutics, Inc.","filed_at":"2025-02-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-02-14","interim":false,"role":"Chief Legal and Administrative Officer","role_category":"general_counsel","successor_name":null,"successor_named":false},"claim":"Jason Duncan was appointed as Chief Legal and Administrative Officer at Neumora Therapeutics, Inc..","evidence_excerpt":"Jason Duncan will serve as Chief Legal and Administrative Officer","confidence":0.8,"filing_url":"https://secwatch.observer/filing/0001193125-25-026156","anchor_url":"https://secwatch.observer/filing/0001193125-25-026156#claim-bcba4e24f6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm"},{"fact_type":"executive_change","fact_key":"d914308747","cik":1885522,"ticker":"NMRA","company_name":"Neumora Therapeutics, Inc.","filed_at":"2025-02-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-02-14","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Michael Milligan was appointed as Chief Financial Officer at Neumora Therapeutics, Inc..","evidence_excerpt":"Michael Milligan will serve as Chief Financial Officer in addition to his current role as principal accounting officer","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-026156","anchor_url":"https://secwatch.observer/filing/0001193125-25-026156#claim-d914308747","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm"},{"fact_type":"executive_change","fact_key":"995a74e38e","cik":1885522,"ticker":"NMRA","company_name":"Neumora Therapeutics, Inc.","filed_at":"2025-02-13T23:59:59+00:00","payload":{"action":"transitioned","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-02-14","interim":false,"role":"Chief Operating and Development Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Bill Aurora changed role as Chief Operating and Development Officer at Neumora Therapeutics, Inc..","evidence_excerpt":"Bill Aurora, Pharm.D. will transition from the role of Chief Strategy Officer to Chief Operating and Development Officer","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-026156","anchor_url":"https://secwatch.observer/filing/0001193125-25-026156#claim-995a74e38e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm"},{"fact_type":"executive_change","fact_key":"15da3792c0","cik":1885522,"ticker":"NMRA","company_name":"Neumora Therapeutics, Inc.","filed_at":"2025-02-13T23:59:59+00:00","payload":{"action":"transitioned","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-02-14","interim":false,"role":"President","role_category":"president","successor_name":null,"successor_named":false},"claim":"Joshua Pinto changed role as President at Neumora Therapeutics, Inc..","evidence_excerpt":"Joshua Pinto, Ph.D. will transition from the role of Chief Financial Officer to President","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-026156","anchor_url":"https://secwatch.observer/filing/0001193125-25-026156#claim-15da3792c0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm"},{"fact_type":"executive_change","fact_key":"475b2f90b6","cik":1885522,"ticker":"NMRA","company_name":"Neumora Therapeutics, Inc.","filed_at":"2025-02-13T23:59:59+00:00","payload":{"action":"departed","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-14","interim":false,"role":"President, Chief Executive Officer","role_category":"ceo","successor_name":"Paul L. Berns","successor_named":true},"claim":"Henry Gosebruch departed as President, Chief Executive Officer at Neumora Therapeutics, Inc..","evidence_excerpt":"Henry Gosebruch will depart the Company and no longer serve as President, Chief Executive Officer or a member of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-026156","anchor_url":"https://secwatch.observer/filing/0001193125-25-026156#claim-475b2f90b6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm"},{"fact_type":"executive_change","fact_key":"ecebe75885","cik":1885522,"ticker":"NMRA","company_name":"Neumora Therapeutics, Inc.","filed_at":"2025-02-13T23:59:59+00:00","payload":{"action":"transitioned","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-02-14","interim":false,"role":"Chief Executive Officer and Chairman of the Board","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Paul L. Berns changed role as Chief Executive Officer and Chairman of the Board at Neumora Therapeutics, Inc..","evidence_excerpt":"Paul L. Berns, the Company’s Co-Founder and Executive Chairman of its Board of Directors (the “Board”), will transition to the roles of Chief Executive Officer and Chairman of the Board","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-026156","anchor_url":"https://secwatch.observer/filing/0001193125-25-026156#claim-ecebe75885","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm"},{"fact_type":"earnings_release","fact_key":"5e4336816c8a57ba219e2c32f7b904838d61e25f","cik":1885522,"ticker":"NMRA","company_name":"Neumora Therapeutics, Inc.","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of $53.7 million","period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-07","result_type":"reported_results","revenue_text":null},"claim":"Neumora Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income net loss of $53.7 million.","evidence_excerpt":"announced its financial results for the first quarter ended March 31, 2024","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-053933","anchor_url":"https://secwatch.observer/filing/0000950170-24-053933#claim-5e4336816c8a57ba219e2c32f7b904838d61e25f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017024053933/0000950170-24-053933-index.htm"}]}